Perspectives on designs of antiandrogens for prostate cancer

University of California San Francisco, Department of Biochemistry and Biophysics, San Francisco, CA941432240, USA +1 415 476 5051
Expert Opinion on Drug Discovery (Impact Factor: 3.54). 10/2007; 2(10):1341-55. DOI: 10.1517/17460441.2.10.1341
Source: PubMed


The androgen receptor (AR) regulates gene transcription in many tissues and is profoundly important in prostate cancer. Antiandrogens compete with the natural hormone and are front line therapeutics to treat prostate cancer. However, antiandrogens frequently become ineffective after prolonged treatment because of development of tumor resistance. This paper reviews design principles for new generations of antiandrogens: super antagonists and surface allosteric modulators. Super antiandrogens are compounds with higher binding affinity than natural agonists and that contain precisely engineered hydrophobic groups that disrupt AR function. AR surface is also an attractive alternative target. Surface inhibitors are small molecules that directly block the receptor-co-activator interface, preventing co-activator recruitment. The challenges to designing these compounds are significant but so is the potential for treatment of the disease.

29 Reads
  • Source
    • "Consequently antagonist-like H12 conformation/s are thought to prevent the correct surface arrangement of AF-2 for productive co-activator binding (78). The AR LBD has also been shown to feature another hydrophobic exposed groove susceptible of pharmaceutical attack called Binding Function 3 (BF-3), which has been shown to modulate coactivator recruitment via allosteric communication and it is hypothesized to be implicated in the recruitment of AR coregulatory proteins and is also an emerging non-LBP druggable site [79] [80] [81] [82] [83] [84] [85] [86] [87]. This surface is adjacent to AF-2 coactivator binding pocket and comprises residues (I672, F673, P723, G724, N727, F826, Q829, Q837, N833 and R84), belonging to H1, H3-5 and H9 [83]. "
    Androgen Receptors: Structural Biology, Genetics and Molecular Defects., 2014 edited by Silvia Socorro, 01/2014: chapter Structural and Functional Analysis of the Androgen Receptor in Disease: pages 53-81; Nova., ISBN: 978-1-62948-693-2
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: When hormone binds to the androgen receptor (AR), the ligand-binding domain (LBD) becomes ordered, displaying a new protein–protein interaction surface called AF2 (coactivator-binding pocket), which is a hydrophobic groove that fits AR coregulators. The association of coregulators with AR LBD is often a critical step for its transcriptional function. Existing pharmaceuticals block AR activity by disrupting AF2 surface's ability to recruit coactivators. Such antagonists bind to the hormone-binding site inside the LBD core and perturb the structure of the most terminal helix of the LBD, distorting the AF2 surface. The AF2 pocket is also a potential candidate for pharmaceutical intervention by surface-directed small molecules that will directly block coactivator recruitment. Such molecules may be a novel generation of antiandrogens for treating prostate cancer.
    Androgen Action in Prostate Cancer, 12/2008: pages 297-311;
  • [Show abstract] [Hide abstract]
    ABSTRACT: In drug discovery, it is essential to identify binding sites on protein surfaces that drug-like molecules could exploit to exert a biological effect. Both X-ray crystallography and NMR experiments have demonstrated that organic solvents bind precisely at these locations. We show that this effect is reproduced using molecular dynamics with a binary solvent. Furthermore, analysis of the simulations give direct access to interaction free energies between the protein and small organic molecules, which can be used to detect binding sites and to predict the maximal affinity that a drug-like molecule could attain for them. On a set of pharmacologically relevant proteins, we obtain good predictions for druggable sites as well as for protein-protein and low affinity binding sites. This is the first druggability index not based on surface descriptors and, being independent of a training set, is particularly indicated to study unconventional targets such as protein-protein interactions or allosteric binding sites.
    Journal of Medicinal Chemistry 04/2009; 52(8):2363-71. DOI:10.1021/jm801385d · 5.45 Impact Factor
Show more